Abstract Number: 323 • ACR/ARP Annual Meeting 2019
Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients
Background/Purpose: Hydroxychloroquine (HCQ) induced retinal toxicity remains a major concern because it can lead to irreversible damage to retinal pigment epithelium and blindness. American Academy…Abstract Number: 1243 • ACR/ARHP Annual Meeting 2018
A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center
Background/Purpose: In 2016, the American Academy of Ophthalmology published revised guidelines on HCQ dosing, recommending a maximum daily dose of 5mg/kg actual body weight as…Abstract Number: 1244 • ACR/ARHP Annual Meeting 2018
Hydroxychloroquine Quality Improvement Project at UF Health Jacksonville Rheumatology Clinics
Background/Purpose: Hydroxychloroquine (HCQ) is a treatment option for lupus erythematosus and rheumatoid arthritis. The risk of retinopathy in the first 5 years of therapy is…Abstract Number: 2034 • ACR/ARHP Annual Meeting 2017
New Guidelines on Hydroxychloroquine Dosage – Where Are We?
Background/Purpose: Hydroxychloroquine (HCQ) is a widely-used medication in many rheumatologic conditions. The most worrisome toxicity is irreversible damage to retinal pigment epithelium which can lead…Abstract Number: 1032 • ACR/ARHP Annual Meeting 2015
Adherence Patterns to American Academy of Ophthalmology Guidelines for Hydroxychloroquine Baseline Screening: Quality Assurance Assessment Utilizing Highmark Claims Data
Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial agent used commonly to treat selected autoimmune rheumatic diseases because of its therapeutic benefits, low cost, and favorable safety…
ACR Meeting Abstracts